Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie Partnership On CD71 Gives CytomX Big Upfront, Co-Promotion Potential

Executive Summary

Antibody-drug conjugates have taken a back seat to cancer immunotherapy as the hot modality in oncology of late, but AbbVie Inc. and CytomX Therapeutics Inc. unveiled a partnership on April 20 to develop an ADC in a deal that CytomX cites as further validation of its Probody technology platform.

Advertisement

Related Content

BIO Notebook, Day 3: Lilly Expands R&D Site, Sigilon Raises Cash And CytomX Talks Deal Strategy
Deal Watch: Success Nets CytomX Another $200m From BMS, Up To $3.6bn For Milestones
AbbVie Partners With Argenx In Cancer Deal Spree
Is the Biotech IPO Window Closing?
Bristol-Myers commits up to $1.2bn in CytomX deal
BioNotebook: Seattle Genetics/AbbVie, Auspex, Flexion, Ironwood
Pfizer enters deal for targeted cancer drugs
Abbott accesses Seattle Genetics' ADC technology for a single oncology target

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC065031

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel